ArrePath
Kurt is a leader in the field of imaging and data sciences and , prior to joining ArrePath, was Senior Director Data Science at Zymergen, where he oversaw the building of a wide variety of data science tools, including statistical models for analysis of high throughput screening and fermentation data, recommendation algorithms for protein sequences catalyzing desired enzymatic functions and prediction of beneficial genetic edits for strain engineering, and chemical machine learning for predicting molecular properties from chemical structures.
Prior to Zymergen, Kurt spent 11 years at UCSF as an adjunct professor and director of the Nikon Imaging Center at UCSF/QB3, a highly successful light microscopy core facility, with 300 annual users and 40 papers published per year. He also ran an NIH-funded research lab that focused development of an integrated microscopy and microfluidic platform to enable highly multiplexed biochemical assays.
Kurt earned a bachelor’s degree in chemistry from Princeton University and a PhD in biophysics from UCSF, where he studied kinesin motility using single molecule imaging. Following UCSF, he was a fellow at the Bauer Center for Genomic Research at Harvard University, where he developed in vivo FRET bioassays.
This person is not in any offices
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.